Trade

with

Cytokinetics Inc
(NASDAQ: CYTK)
AdChoices
3.50
+0.05
+1.45%
After Hours :
3.50
0.00
0.00%

Open

3.49

Previous Close

3.45

Volume (Avg)

119.66k (391.92k)

Day's Range

3.37-3.50

52Wk Range

3.05-13.26

Market Cap.

128.13M

Dividend Rate ( Yield )

-

Beta

1.32

Shares Outstanding

36.61M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 30.65M

    • Net Income

    • -33.72M

    • Market Cap.

    • 128.13M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -51.98

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.32

    • Forward P/E

    • -2.48

    • Price/Sales

    • 2.53

    • Price/Book Value

    • 1.63

    • Price/Cash flow

    • -3.74

      • EBITDA

      • -33.46M

      • Return on Capital %

      • -24.31

      • Return on Equity %

      • -35.47

      • Return on Assets %

      • -24.31

      • Book Value/Share

      • 2.15

      • Shares Outstanding

      • 36.61M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 13.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.41

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 671.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 19.80

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -51.98

            • 39.38

            • Net Profit Margin

            • -51.98

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -745.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -762.40

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 4.73

              • 2.92

              • Quick Ratio

              • 4.61

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.22

              • 2.21

              • Book Value/Share

              • 2.15

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.74

                • 217.39

                • P/E Ratio 5-Year High

                • -42.34

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.24

                • 124.82

                • Price/Sales Ratio

                • 2.46

                • 9.52

                • Price/Book Value

                • 1.59

                • 8.61

                • Price/Cash Flow Ratio

                • -3.74

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -35.47

                        (-47.00)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -24.31

                        (-41.90)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -35.47

                        (-47.00)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.47

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -33.89M
                      Operating Margin
                      -110.59
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -3.74
                      Ownership

                      Institutional Ownership

                      78.06%

                      Top 10 Institutions

                      47.79%

                      Mutual Fund Ownership

                      19.77%

                      Float

                      99.74%

                      5% / Insider Ownership

                      1.54%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,063,466

                      • 0.00

                      • 2.90

                      • Vanguard Total Stock Mkt Idx

                      •  

                        548,302

                      • 0.00

                      • 1.50

                      • iShares Russell 2000 (AU)

                      •  

                        514,940

                      • -1.46

                      • 1.38

                      • Fidelity® Small Cap Stock Fund

                      •  

                        413,702

                      • 55.82

                      • 1.13

                      • TIAA-CREF Small-Cap Equity

                      •  

                        387,776

                      • 0.00

                      • 1.06

                      • Vanguard Extended Market Index Fund

                      •  

                        360,121

                      • 0.00

                      • 0.98

                      • Allianz Biotechnologie

                      •  

                        267,460

                      • 0.00

                      • 0.72

                      • iShares Russell 2000 Value

                      •  

                        231,978

                      • 0.26

                      • 0.62

                      • CREF Stock

                      •  

                        192,904

                      • -17.26

                      • 0.53

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Lansdowne Partners Limited Partnership

                      •  

                        2,321,865

                      • 0.00%

                      • 6.34

                      • Pyramis Global Advisors, LLC

                      •  

                        1,563,224

                      • +87.33%

                      • 4.27

                      • Fidelity Management and Research Company

                      •  

                        1,520,132

                      • +22.45%

                      • 4.15

                      • BlackRock Fund Advisors

                      •  

                        1,341,188

                      • +13.05%

                      • 3.66

                      • Bvf Inc

                      •  

                        1,317,000

                      • +1,145.92%

                      • 3.60

                      • Vanguard Group, Inc.

                      •  

                        1,211,321

                      • +8.60%

                      • 3.31

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Cytokinetics Inc was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that...more modulate muscle function for the potential treatment of serious diseases and medical conditions. Its research and development activities relating to the biology of muscle function have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Its advanced research and development programs relates to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. It also conducts earlier-stage research dire...morected to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. Its drug candidate from its skeletal muscle contractility program, tirasemtiv, formerly known as CK-2017357, is a fast skeletal muscle troponin activator. The Company's cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. Its drug candidate from this program, omecamtiv mecarbil, formerly known as CK-1827452, is a novel cardiac muscle myosin activator that is being developed under a strategic alliance with Amgen. It is conducting joint research with Amgen directed to next-generation compounds in its cardiac muscle contractility program. The Company is currently conducting a Phase II clinical trials program for tirasemtiv, including an ongoing Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS, Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS. It is also developing CK-2127107, a structurally distinct, fast skeletal muscle troponin activator, under a strategic alliance with Astellas. The Company competes with Mitsubishi Tanabe Pharma Corporation, Eisai Inc., Trophos SA, Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., GlaxoSmithKline plc., BrainStorm Cell Therapeutics and Neuralstem. The Company's research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States.lessless

                      Key People

                      Robert I. Blum

                      CEO/President/Director

                      Dr. L. Patrick Gage,PhD

                      Director/Chairman of the Board

                      Sharon Surrey-Barbari

                      CFO/Chief Accounting Officer/Secretary/Executive VP, Divisional

                      Dr. Wendell D. Wierenga,PhD

                      Director

                      Ms. B. Lynne Parshall, J.D.

                      Director

                      • Cytokinetics Inc

                      • 280 East Grand Avenue

                      • South San Francisco, CA 94080

                      • USA.Map

                      • Phone: +1 650 624-3000

                      • Fax: +1 650 624-3010

                      • cytokinetics.com

                      Incorporated

                      1997

                      Employees

                      85

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: